Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
45
ACAD Quote, Financials, Valuation and Earnings
Last price:
$17.21
Seasonality move
:
11.24%
Day range:
$17.05 - $17.64
52-week range:
$14.15 - $31.10
Dividend yield:
0%
P/E ratio:
22.56x
P/S ratio:
3.14x
P/B ratio:
5.07x
Volume:
2.5M
Avg. volume:
3.2M
1-year change:
-41.59%
Market cap:
$2.9B
Revenue:
$726.4M
EPS (TTM):
$0.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$279M | $0.21 | 22.45% | -18.66% | $24.95 |
|
CORT
Corcept Therapeutics
|
$198.9M | $0.37 | 46.26% | 36.61% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | -60.77% | -99.16% | $7.30 |
|
PFE
Pfizer
|
$17.1B | $0.46 | 27.51% | 12.4% | $31.78 |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -25% | -- |
|
VSTM
Verastem
|
$150K | -$0.74 | -- | -28.48% | $12.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$17.60 | $24.95 | $2.9B | 22.56x | $0.00 | 0% | 3.14x |
|
CORT
Corcept Therapeutics
|
$51.69 | -- | $5.4B | 41.02x | $0.00 | 0% | 9.16x |
|
NBY
NovaBay Pharmaceuticals
|
$0.64 | $7.30 | $3.1M | -- | $0.00 | 0% | 0.07x |
|
PFE
Pfizer
|
$26.86 | $31.78 | $152.2B | 36.30x | $0.42 | 6.26% | 2.57x |
|
PTN
Palatin Technologies
|
$1.20 | -- | $23.5M | -- | $0.00 | 0% | -- |
|
VSTM
Verastem
|
$5.90 | $12.29 | $262.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
-- | -0.273 | -- | 1.96x |
|
CORT
Corcept Therapeutics
|
-- | 2.876 | -- | 3.49x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.365 | 1.51% | 0.75x |
|
PFE
Pfizer
|
41.92% | 0.489 | 40.56% | 0.64x |
|
PTN
Palatin Technologies
|
-- | -3.016 | -- | 0.99x |
|
VSTM
Verastem
|
50.52% | -0.102 | 40.34% | 3.10x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$231.5M | $31.6M | 27.32% | 27.32% | 12.64% | $63.2M |
|
CORT
Corcept Therapeutics
|
$179.7M | $46.6M | 25.77% | 25.77% | 25.53% | $72.2M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PFE
Pfizer
|
$12.4B | $5.3B | 2.66% | 4.63% | 31.06% | $6.1B |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
VSTM
Verastem
|
-- | -$37M | -78.01% | -120.71% | -71.18% | -$23.8M |
ACADIA Pharmaceuticals vs. Competitors
-
Which has Higher Returns ACAD or CORT?
Corcept Therapeutics has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of 25.86%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Corcept Therapeutics's return on equity of 25.77%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals92.47% $0.20 $577.2M CORTCorcept Therapeutics98.43% $0.41 $638.8M -
What do Analysts Say About ACAD or CORT?
ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 41.75%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 44.9%. Given that Corcept Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 6 0 CORTCorcept Therapeutics3 0 0 -
Is ACAD or CORT More Risky?
ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.46%.
-
Which is a Better Dividend Stock ACAD or CORT?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or CORT?
ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than Corcept Therapeutics quarterly revenues of $182.5M. ACADIA Pharmaceuticals's net income of $32.8M is lower than Corcept Therapeutics's net income of $47.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 22.56x while Corcept Therapeutics's PE ratio is 41.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.14x versus 9.16x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals3.14x 22.56x $250.4M $32.8M CORTCorcept Therapeutics9.16x 41.02x $182.5M $47.2M
-
Which has Higher Returns ACAD or NBY?
NovaBay Pharmaceuticals has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 27.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals92.47% $0.20 $577.2M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About ACAD or NBY?
ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 41.75%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 483.4%. Given that NovaBay Pharmaceuticals has higher upside potential than ACADIA Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 6 0 NBYNovaBay Pharmaceuticals2 0 0 -
Is ACAD or NBY More Risky?
ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.
-
Which is a Better Dividend Stock ACAD or NBY?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or NBY?
ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $32.8M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 22.56x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.14x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals3.14x 22.56x $250.4M $32.8M NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns ACAD or PFE?
Pfizer has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of 25.23%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Pfizer's return on equity of 4.63%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals92.47% $0.20 $577.2M PFEPfizer70.27% $0.78 $159.2B -
What do Analysts Say About ACAD or PFE?
ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 41.75%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that ACADIA Pharmaceuticals has higher upside potential than Pfizer, analysts believe ACADIA Pharmaceuticals is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 6 0 PFEPfizer8 13 1 -
Is ACAD or PFE More Risky?
ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.
-
Which is a Better Dividend Stock ACAD or PFE?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or PFE?
ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are smaller than Pfizer quarterly revenues of $17.7B. ACADIA Pharmaceuticals's net income of $32.8M is lower than Pfizer's net income of $4.5B. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 22.56x while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.14x versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals3.14x 22.56x $250.4M $32.8M PFEPfizer2.57x 36.30x $17.7B $4.5B
-
Which has Higher Returns ACAD or PTN?
Palatin Technologies has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -2357.27%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals92.47% $0.20 $577.2M PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About ACAD or PTN?
ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 41.75%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1316.67%. Given that Palatin Technologies has higher upside potential than ACADIA Pharmaceuticals, analysts believe Palatin Technologies is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 6 0 PTNPalatin Technologies0 0 0 -
Is ACAD or PTN More Risky?
ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.
-
Which is a Better Dividend Stock ACAD or PTN?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or PTN?
ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than Palatin Technologies quarterly revenues of $350K. ACADIA Pharmaceuticals's net income of $32.8M is higher than Palatin Technologies's net income of -$7.8M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 22.56x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.14x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals3.14x 22.56x $250.4M $32.8M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns ACAD or VSTM?
Verastem has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -82.56%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Verastem's return on equity of -120.71%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals92.47% $0.20 $577.2M VSTMVerastem-- -$0.60 $80.9M -
What do Analysts Say About ACAD or VSTM?
ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 41.75%. On the other hand Verastem has an analysts' consensus of $12.29 which suggests that it could grow by 108.23%. Given that Verastem has higher upside potential than ACADIA Pharmaceuticals, analysts believe Verastem is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 6 0 VSTMVerastem6 0 0 -
Is ACAD or VSTM More Risky?
ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Verastem has a beta of 0.237, suggesting its less volatile than the S&P 500 by 76.284%.
-
Which is a Better Dividend Stock ACAD or VSTM?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or VSTM?
ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than Verastem quarterly revenues of $10M. ACADIA Pharmaceuticals's net income of $32.8M is higher than Verastem's net income of -$24M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 22.56x while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.14x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals3.14x 22.56x $250.4M $32.8M VSTMVerastem-- -- $10M -$24M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 7.07% over the past day.
Sell
47
CEG alert for Jan 10
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
8
CRNX alert for Jan 10
Crinetics Pharmaceuticals [CRNX] is down 16.31% over the past day.
